Beli Lucius Niraparib dalam talian
Beli Lucius Niraparib dalam talian

Beli Lucius Niraparib dalam talian

EUR 173.33

1,000+ vendus
Prix promo

Pharmacie physique à Hong Kong, authenticité 100% garantie

Points forts

Indicated as maintenance treatment for advanced ovarian, fallopian tube, or primary peritoneal cancer that has responded to platinum-based chemotherapy, particularly in patients with HRD-positive disease or a germline BRCA mutation.

Garanties de service

Expédition transfrontalièrePharmacie agrééeContrôle pharmacienGarantie authenticité

Caractéristiques

Spécification
100mg*30 comprimes
Fabricant
Lucius Pharmaceuticals
Expédition
Hong Kong

10000 en stock

Catégorie : Étiquettes : , , Marque :

Informations produit

Nom anglais
Niraparib
Nom générique
Niraparib

Caractéristiques

Spécification
100mg*30 comprimes
Fabricant
Lucius Pharmaceuticals
Expédition
Hong Kong

Détails complets

Indications

Indicated as maintenance treatment for advanced ovarian, fallopian tube, or primary peritoneal cancer that has responded to platinum-based chemotherapy, particularly in patients with HRD-positive disease or a germline BRCA mutation.

Mécanisme d’action

PARP ， PARP-1 PARP-2， DNA ， PARP PARP-DNA ， DNA BRCA1/2 BRCA1/2 HRD BRCA1/2 ，

Pharmacologie

12.1 Mecanisme d action PARP ， PARP-1 PARP-2， DNA ， PARP PARP-DNA ， DNA BRCA1/2 BRCA1/2 HRD BRCA1/2 ，

Posologie

2.1 BRCA2 AKEEGA mCSPC [ (14.1)] BRCA AKEEGA mCRPC [ (14.2)] FDA ， BRCA2 (BRCA2m) (mCSPC) AKEEGA 200 mg /1000 mg ， 5 mg ， BRCA BRCAm mCRPC AKEEGA 200 /1,

Precautions

5.1 / AKEEGA / (MDS/AML) AMPLITUDE MAGNITUDE ， AKEEGA ，MDS AML 0.6% (2/347) 0.5% (1/212)， AKEEGA MDS/ AML ， / DNA MDS/AML ， MDS/AML， AKEEGA

Interactions médicamenteuses

7.1 AKEEGA CYP3A4 CYP3A4 [ (12.3)] CYP3A4 CYP3A4 [ (12.3)]， 7.2 AKEEGA CYP2D6 ， CYP2D6 ，

Effets indésirables

/ [ Precautions(5.1)] [ Precautions(5.2)] [ Precautions(5.3)] [ Precautions(5.4)] [ Precautions(5.5)] [ Precautions(5.6)] 223 [ Precautions(5.7)] [ Precautions(5.8)] 6.1

Conservation

AKEEGA® AKEEGA 50 /500 ， ， ， “N 50 A”， 60 NDC 57894-050-60 AKEEGA 100 /500 ， ， ， “N 50 A”，

Package Insert

Ingredients

11 AKEEGA® ADP- PARP 2-{4-[(3S)- -3- ] }-2H- 7- 4- 1:1:1 C₂₆H₃₀N₄O₅S， 510.61 g/mol

Indications

Indicated as maintenance treatment for advanced ovarian, fallopian tube, or primary peritoneal cancer that has responded to platinum-based chemotherapy, particularly in patients with HRD-positive disease or a germline BRCA mutation.

Posologie

2.1 BRCA2 AKEEGA mCSPC [ (14.1)] BRCA AKEEGA mCRPC [ (14.2)] FDA ， BRCA2 (BRCA2m) (mCSPC) AKEEGA 200 mg /1000 mg ， 5 mg ， BRCA BRCAm mCRPC AKEEGA 200 /1,

Effets indésirables

/ [ Precautions(5.1)] [ Precautions(5.2)] [ Precautions(5.3)] [ Precautions(5.4)] [ Precautions(5.5)] [ Precautions(5.6)] 223 [ Precautions(5.7)] [ Precautions(5.8)] 6.1

Precautions

5.1 / AKEEGA / (MDS/AML) AMPLITUDE MAGNITUDE ， AKEEGA ，MDS AML 0.6% (2/347) 0.5% (1/212)， AKEEGA MDS/ AML ， / DNA MDS/AML ， MDS/AML， AKEEGA

Use in Pregnancy and Lactation

8.1 AKEEGA Mecanisme d action[ (12.1)]，AKEEGA AKEEGA / - ， ， [ Precautions (5.2) (13.1)] Mecanisme d action ，

Interactions médicamenteuses

7.1 AKEEGA CYP3A4 CYP3A4 [ (12.3)] CYP3A4 CYP3A4 [ (12.3)]， 7.2 AKEEGA CYP2D6 ， CYP2D6 ，

Clinical Pharmacology

12 12.1 Mecanisme d action PARP ， PARP-1 PARP-2， DNA ， PARP PARP-DNA ， DNA BRCA1/2 BRCA1/2 HRD BRCA1/2 ， ， ， 17α- /C17,20-

Clinical Studies

14 14.1 BRCA2 (mCSPC) AKEEGA AMPLITUDE (NCT04497844) ， 696 (HRR) (HRRm) mCSPC ， 1:1 ， 200 mg 1000 mg (n=348) (n=348) 5 mg， 14 (ADT) mCSPC ， 45 6 6 ADT HRR BRCA2 CDK12

Conservation

AKEEGA® AKEEGA 50 /500 ， ， ， “N 50 A”， 60 NDC 57894-050-60 AKEEGA 100 /500 ， ， ， “N 50 A”，

Avis produit (17)

Filtre : Tous les avis
4.8★★★★★
17 avis clients14 achats verifies
+o***e· il y a 3 semaines
★★★★
+t***3· il y a 1 mois
Achat verifie
★★★★★

Description

Indications

Indicated as maintenance treatment for advanced ovarian, fallopian tube, or primary peritoneal cancer that has responded to platinum-based chemotherapy, particularly in patients with HRD-positive disease or a germline BRCA mutation.

Mécanisme d’action

PARP ， PARP-1 PARP-2， DNA ， PARP PARP-DNA ， DNA BRCA1/2 BRCA1/2 HRD BRCA1/2 ，

Pharmacologie

12.1 Mecanisme d action PARP ， PARP-1 PARP-2， DNA ， PARP PARP-DNA ， DNA BRCA1/2 BRCA1/2 HRD BRCA1/2 ，

Posologie

2.1 BRCA2 AKEEGA mCSPC [ (14.1)] BRCA AKEEGA mCRPC [ (14.2)] FDA ， BRCA2 (BRCA2m) (mCSPC) AKEEGA 200 mg /1000 mg ， 5 mg ， BRCA BRCAm mCRPC AKEEGA 200 /1,

Precautions

5.1 / AKEEGA / (MDS/AML) AMPLITUDE MAGNITUDE ， AKEEGA ，MDS AML 0.6% (2/347) 0.5% (1/212)， AKEEGA MDS/ AML ， / DNA MDS/AML ， MDS/AML， AKEEGA

Interactions médicamenteuses

7.1 AKEEGA CYP3A4 CYP3A4 [ (12.3)] CYP3A4 CYP3A4 [ (12.3)]， 7.2 AKEEGA CYP2D6 ， CYP2D6 ，

Effets indésirables

/ [ Precautions(5.1)] [ Precautions(5.2)] [ Precautions(5.3)] [ Precautions(5.4)] [ Precautions(5.5)] [ Precautions(5.6)] 223 [ Precautions(5.7)] [ Precautions(5.8)] 6.1

Conservation

AKEEGA® AKEEGA 50 /500 ， ， ， “N 50 A”， 60 NDC 57894-050-60 AKEEGA 100 /500 ， ， ， “N 50 A”，